We are pleased to announce the launch of Estaporin®️ in collaboration with Cureleads, our strategic partner in MENA.
We are pleased to announce the launch of Estaporin®️ in Middle East, beginning with Lebanon. This is the first generic
Cyclosporin eyedrops using cutting-edge Micellar Nano Particle (MNP) technology of SGN Nanopharma, which significantly
enhances absorption and efficacy of the product.
This innovative solution marks a significant milestone in our shared mission to make quality, affordable medicine
accessible to all. With this launch, we are paving the way for improved eye care, ensuring that patients receive the
best treatment at a right price.
We are pleased to announce our collaboration with BrainCapture for BC-1, the first global point-of-care EEG
device that
makes neurodiagnostics accessible to all.
Effective from: 24th June, 2024
Wellesta and BrainCapture, a Medical Technology company based in Denmark, have signed a sales, marketing &
distribution
agreement for BC-1 to commercialise the device in SEA markets, followed by India and other ASEAN countries.
BC-1 is a portable, easy-to-use, and affordable CE-marked mobile EEG diagnostic system designed to make EEG
accessible
anywhere it's needed. BC-1 includes a smartphone application and quality control algorithm that allows
non-expert
medical workers with little to no EEG experience to efficiently collect high-quality EEG data with only a short
training. BrainCapture’s BC-1 system also includes robust cloud tools that provide a centralized, secure
platform for
the remote reading and interpretation of EEG by neurological experts. BC-1’s unique combination of portability,
connectivity, and usability enables experts to provide point of care diagnosis to many more patients than
previously
possible.
Describing the partnership, Co-Founder & CCO of Brain Capture Paul Loomis said, “We are very happy to
collaborate with
Wellesta to commercialize BrainCapture’s BC-1. Neurological conditions are a leading cause of disability, and
this
burden is worsened by a lack of access to neurodiagnostic tools like EEG. Our solution was designed with this
problem in
mind. A fast-paced company like Wellesta, with a significant presence in key markets and exposure to the experts
who
drive uptake of innovations like ours, is the perfect partner for commercialization. We are confident in
achieving our
goal of democratizing EEG in these markets.”
The Chairman and Managing Director of Wellesta, Mr. Milan Paleja, added, “This revolutionary approach to EEG
improves
access to critical diagnostics, thus bringing affordable EEG recordings and interpretations to everyone. This
aligns
with Wellesta’s objective to provide high-quality, right-priced innovative products for better patient
outcomes.”
We are pleased to announce the appointment of Dimple Lalwani as Head of Finance for Wellesta
Group with effect from 1st June 2024
Effective from 1st Jun, 2024
Dimple Lalwani has been appointed as Head of Finance for Wellesta Group with effect from 1st
June, 2024. She is a seasoned finance leader with over 20 years of experience in FP&A,
Controllership, and Audits, with a proven track record of building high-performing teams.
Dimple has worked in Novartis for the last 13 years, leading financial and strategic planning, and
internal audit for Novartis India. In her last role, she was the Regional Franchise Finance lead for
Region APMA, based in Singapore. She has also worked with companies like L'Oréal, Castrol,
and Monsanto in various roles, including financial planning, team leadership of accounts, and as
a management controller.
She has successfully driven profitability improvements at country and regional levels, led ERP
implementations, and simplified processes. She is known for leading with empathy and working
collaboratively with diverse teams. She is results-oriented and passionate about continuous
learning and creating value.
Dimple is a Chartered Accountant from the Indian Institute of Chartered Accountants and has
also completed a certification in Venture Entrepreneurial Finance from Oxford University.
We are sure that Dimple’s experience and leadership will help achieve our vision and mission.
She will report to Milan Paleja, Chairman and Managing Director of Wellesta Group and lead
Country finance and HQ finance team.
We welcome Dimple Lalwani to the Wellesta family and wish her great success in her new
position.
We are pleased to announce our strategic partnership with Melody International, Japan for commercialising Wearable Fetal Monitor iCTG in Asian countries.
Effective from 22nd Jun, 2024
Wellesta and Melody International, Japan have signed an agreement for sales, marketing and distribution of Wearable Fetal Monitor iCTG for Asian markets.
This is a cloud-type mobile wireless fetal monitor which is already in use in Japan for the past few years, can be used Anywhere at Any time providing smarter way to
check maternal & fetal conditions.
This product is one-of-a-kind instruments in the world for fetal and maternal monitoring where remote access and monitoring allows high-risk expectant mothers'
conditions to be monitored from a distance, which can help reduce the likelihood of emergency deliveries by providing early screening. The efficient use of wait time
is facilitated by the device being battery-operated and cable-free, allowing it to be used during outpatient waiting periods and thereby reducing overall checkup time
and maternal stress.
The real-time transmission feature during emergency transfers, enables the device to be used in an ambulance, providing real-time data to the accepting hospital,
which can better prepare for the mother's arrival (with an optional real-time cloud feature). More so, it has a built-in speaker in the transducer, so it can be
used as a fetal doppler, thus streamlining the process of fetal monitoring.
While talking about this partnership, Yhuko Ogata, Founder & CEO of Melody International said, “We are extremely happy to join hands with Wellesta to
commercialise Wearable Fetal Monitor iCTG, the Future of Perinatal e-Health, for expectant mother’s safe and secure deliveries around the world. With a
fast-growing company like Wellesta, we are definite to achieve our goal to provide this compact and smart technology to the Asian markets.”
The Chairman and Managing Director, Mr. Milan Paleja added, “Wearable Fetal Monitor iCTG marks a significant advancement in maternal & fetal monitoring,
thereby reducing perinatal stress and assisting doctors swiftly in challenging situations. This aligns with Wellesta’s objective to provide high quality,
right priced innovative products for better patient outcomes.”
We are pleased to announce the partnership with Butterfly Network, Inc. to market and distribute Point-Of-Care Ultrasound (POCUS) Butterfly Human and Butterfly Vet in South-East Asian countries.
Effective from 12th Mar, 2024
Wellesta, a healthcare company headquartered in Singapore, unveils the partnership with Butterfly Network Inc., a medical devices manufacturer based in USA, for sales, marketing & distribution of its Point-Of-Care Ultrasound Butterfly Human and Butterfly Vet, thereby adding additional products in their MedTech vertical for the South-east Asian market.
In preparation for the launch and to onboard the employees and doctors in Singapore and Malaysia, Wellesta conducted training program where Dr. Peter Weimersheimer & Mohamed Hassan conducted the training sessions for Butterfly Human in Singapore and Dr. David Rousseau & Mrs. Jenna Mutch demonstrated the usage of the Butterfly Vet in Malaysia.
Jonathan M. Rothberg, Founder of Butterfly Network said, "With our mission to democratize healthcare by making medical imaging accessible to everyone around the world, this is a significant step forward to serving the healthcare community in South-east Asia. With our commitment to innovation and excellence, we aim to make a positive impact on patient outcomes in South-east Asia and beyond."
Milan Paleja, Chairman & M.D. of Wellesta added "We are very happy to introduce this POCUS Butterfly Human and Butterfly Vet in South-east Asian market which will help patient’s early diagnosis and provide support for the doctors & veterinarians. This move underscores Wellesta's ongoing efforts to provide superior quality & innovative healthcare solutions at right price for better patient outcomes.”
We are pleased to announce the collaboration with Escala Medical for the launch of Innovative product for pelvic prolapse in women in Asia.
Effective from 12th May, 2024
It brings us immense pleasure to announce our collaboration for the launch of an innovative product developed by Escala Medical,
led by Edit Goldberg to address significant need in women's health. The product we are introducing offers a solution for millions of women who
suffer from pelvic prolapse.
This innovative solution will make a meaningful difference in the lives of countless mothers and women, empowering them to lead healthier and more comfortable lives.
As we celebrate Mother's Day, let us look forward to the positive impact our product will have on the lives of mothers in Asia.
Wellesta acquires minority shares in Cureleads - UAE, our Partner in MENA
Effective from 13th Dec, 2023
We are excited to announce that Wellesta has acquired minority shares in Cureleads, a fast-growing BioPharma company in
MENA. Through this investment, we aim to strengthen our collaboration and march towards accomplishing our objectives in
MENA region.
This strategic move demonstrates our strong commitment to fostering long-term relationships with Cureleads who share our
vision of providing access to high quality healthcare solutions at right price for better patient outcomes.
By leveraging the expertise and resources of both organizations, we are poised to accelerate the development and
delivery of groundbreaking therapies that address unmet medical needs.
We are confident that this partnership will yield significant benefits for both companies and, more importantly, for
patients who rely on innovative, high-quality solutions to improve their lives.
We look forward to the opportunities that lie ahead as we embark on this exciting journey together.
We are pleased to announce that IntelliMed Healthcare Solutions that offers Medical Affairs solutions in Healthcare
Industry, is now a Wellesta Group Company
Effective from 19th Sept 2023
IntelliMed Healthcare Solutions is a Scientific Partner that collaborates with Healthcare companies to provide
innovative and practical solutions in the area of Medical Affairs, Medical Writing, Real World Evidence generation in
areas of Pharmaceuticals, Medical devices and Nutraceuticals.
As a Medical affairs company, IntelliMed Healthcare Solutions supports the Healthcare Industry in identifying the
healthcare products backed by Data and Evidence & supports them with right information to enable the physicians to
effectively treat their patients and achieve superior patient outcomes. This is done through patient and physician
education and support to the physicians, policy makers and payers with right clinical data.
Speaking about this new development, Mr. Milan Paleja, Chairman & Managing Director of the Wellesta Group welcomes
“IntelliMed as a part of Wellesta Group Companies, which will help strengthen the science to support Wellesta’s
Subsidiaries & our Clients. Innovation is one of the pre-dominant drivers of the current times and with this
enhancement, Wellesta will be a strong supporter of helping to provide quality healthcare solutions to a larger patient
group at a right price, with increased support of Science.” Via our own Medical Team from Intellimed !
Dr. Anish Desai, Founder & CEO, IntelliMed, said “IntelliMed brings in the capability to provide the Data,
Differentiation, Dissemination and Diligence to manage the challenges of the Healthcare Ecosystems. Appropriate AI and
Digital tools will be used to get the desired results which will support Wellesta’s objectives.”
About Wellesta:
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market presence in Southeast
Asia & India and partnering in MENA. We aim to serve clients and consumers through commercial and marketing support
using an innovative approach across the Wellesta value chain. We work with companies to expand their presence in
Southeast Asia & India as a strategic partner for companies present in these markets and act as a representative for
companies that are not present in these markets and would like to sell/market their products in the region.
Wellesta Holdings operate in a spectrum of business verticals under our partner brands and own brands including
pharmaceutical, nutraceuticals, OTC and medical devices, led by industry-proven leaders at HQ & Country level. Wellesta
works as an extended arm for our principals through win-win partnership and provides superior quality products and
services at the right price, by working at full compliance and transparency in our business approach.
IntelliMed Health Solutions is one of the experienced players in the Healthcare Ecosystem to provide pragmatic solutions
related to the growth of the healthcare industry. Key objective is to provide innovative and practical solutions in the
area of Medical Affairs & Market Access, Clinical & Economic evidence, Regulatory services for Pharmaceuticals, Medical
devices, and Nutraceutical companies to achieve superior patient outcomes.
IntelliMed has the expertise & experience to support every product with scientific backed data, which will help the
healthcare companies to better connect, communicate, and convince the Stakeholders. It helps in differentiating their
product in a crowded competitive environment and delivering the products true value.
We are pleased to announce the appointment of Subhashini Kannanyadu as Regulatory Affairs Manager for Wellesta Malaysia & Region Lead.
Effective from 4th Nov, 2024
Subhashini Kannanyadu has been appointed as Regulatory Affairs Manager for Malaysia business & Region Lead for Wellesta Group. She joins us with 8 years of experience in regulatory affairs and compliance across the pharmaceutical, supplements, and medical devices sectors.
Subhashini’s most recent role was with Solventum (formerly 3M Healthcare), where she led a team managing the Malaysia and Singapore markets, with responsibilities spanning regulatory submissions, compliance updates, and policy adherence. Her role as a licensed pharmacist and regulatory advisor made her an essential member of her leadership team, facilitating efficient product approvals and strategic regulatory planning. Known for her collaborative approach and strong communication skills, Subhashini brings a relationship-focused leadership style to Wellesta.
Her depth of experience includes managing poison licenses, regulatory operations for complex portfolios, and maintaining compliance with international and local standards (NPRA, MDA, HSA). Subhashini’s achievements also reflect her proactive management of industry changes, ensuring full regulatory compliance in evolving markets.
Subhashini Kannanyadu holds a Bachelor of Pharmacy (Hons.) degree and is a Registered Pharmacist. She is a Life Member at the Malaysian Pharmaceutical Society (MPS) since January 2019.
Her strong commitment to expanding her expertise in the healthcare industry, which aligns well with Wellesta’s objectives for growth and excellence in this field, will help us achieve our vision and mission. We are confident that her experience and leadership will be instrumental in driving our regulatory affairs efforts.
She will report to Sally Kuah, Country Head of Wellesta Healthcare, Malaysia and will report to Mr. Milan Paleja, Chairman and MD of Wellesta Group for her regional regulatory role.
We welcome Subhashini Kannanyadu to the Wellesta family and wish her great success in her new role.
We are pleased to announce the appointment of Dr. Kamarul Hafiz Rahmat, MD, as Head of Sales & Marketing for Medical Devices & Diagnostics Business for Wellesta HQ, effective from November 1, 2024.
Effective from 1st Nov, 2024
Dr. Kamarul Hafiz Rahmat has been appointed as Head of Sales & Marketing for Medical Devices & Diagnostics Business for Wellesta HQ. Prior to joining Wellesta, Dr. Kamarul worked as Senior Product Manager for Anaesthesia & Emergency Medicine at Teleflex Incorporated.
He brings 12 years of experience in the Medical Device industry, including eight years in regional roles across Southeast Asia, Taiwan, Hong Kong, and Pakistan where he focused on sales, product management, and marketing of medical devices, particularly in the Ultrasound sector. He worked with esteemed brands such as GE Healthcare, Teleflex, Siemens Healthineers, Mindray, and Fresenius Kabi.
Dr. Kamarul began his career as a Medical Doctor in Malaysia before transitioning to the distributor company Maycare where he worked as National Sales Manager, managing products like ultrasound, CTG, ECG, Monitors, GA Machines and Ventilators. He then joined GE Healthcare, where he served as a Clinical Specialist, later moving into Product Sales and Marketing roles. At GE, he managed the Point of Care Ultrasound portfolio, covering the ASEAN market and serving clients in Anaesthesia, Intensive care, and Emergency Medicine. He was also in charge of developing GE ultrasound market for Sports Medicine, Physiotherapy and Veterinary sectors.
In 2022, Dr. Kamarul joined Teleflex, where his responsibilities expanded to overseeing the Anaesthesia and Emergency Medicine portfolios, along with the Military market, across ASEAN, Taiwan, Hong Kong, Pakistan, Mongolia, and Nepal. He was responsible for airway products like LMAs and ETTs, as well as emergency medicine and military products like intraosseous devices and combat gauze.
Dr. Kamarul holds an MBBS degree from Kursk State Medical University in Russia and worked as a Medical Officer in Sultanah Bahiyah Hospital in Kedah, Malaysia.
We are sure that Dr. Kamarul’s rich experience in Medical Devices & Diagnostics industry will strengthen our MD&D vertical, helping us achieve our business objectives. He will report to Mr. Milan Paleja, Chairman and Managing Director of Wellesta Group.
We welcome Dr. Kamarul Hafiz Rahmat and wish him great success in his new position.
We are pleased to announce the appointment of Anne Juliah as Regional Head, DTC for
Wellesta with effect from 15th Jul, 2024
Effective from 15th Jul, 2024
Anne Juliah is a seasoned commercial leader with 20+ years of diverse experiences in Multi-national
pharmaceutical, Healthcare and FMCG companies. Prior to joining Wellesta, Anne was the
APAC Regional Head of Retail Sales at Abbott Laboratories. In this role she spearheaded
strategic growth opportunities of retail and e-commerce sales, the fastest growing channel
for the company.
Prior to her tenure at Abbott, she worked at Johnson & Johnson for 13 years, progressing
from Brand Manager to Regional Sales Manager in Indonesia before being promoted to
APAC Regional Franchise Head for Smoking Cessation & Digestive Health. Earlier in her
career Anne worked for Philip Morris International and GlaxoSmithKline in multiple roles
including Field Sales, Consumer Insights and Brand Management.
Anne holds a Master’s degree in Business Administration and a Bachelor’s degree in
Environmental Engineering, each accredited from the Institute of Technology Bandung,
Indonesia.
We at Wellesta are very optimistic about SEA & Indian Healthcare markets and see
opportunities for Wellesta to progress. We are sure that Anne’s rich experience and
leadership will help achieve our vision and mission. She will report to Milan Paleja, Chairman
and MD of Wellesta Group.
We welcome Ms. Anne Juliah to the Wellesta family and wish her great success in this new
position.
We are pleased to announce the appointment of Dr. Beat Sumegi as Regional Head/Managing Director of the Wellesta Group for Europe Business, effective from 1st June 2024.
Effective from 1st Jun, 2024
Dr. Beat Sumegi has been appointed as Regional Head/Managing Director of Wellesta Group for Europe business. Prior to joining Wellesta, he was the Global Head for Medical Excellence & Operations for Galderma S.A, Switzerland.
Dr. Beat is a seasoned Medical & Business leader with close to 30 years of extensive experience in the Pharma industry. He started his career as a Physician for
4 years in Austria, S. Africa and Switzerland. Later he held various leadership roles across different cultures and geographies in Medical Affairs, R&D and Commercial
with expertise in General Management, Board-level interaction, Commercial Strategy, Sales & Marketing, Market Access, Medical Affairs, Digital Innovation.
He is a patient-centric Senior Pharma Executive, successfully leveraging his experience as accomplished physician in strategic & operational roles across different
pharmaceutical divisions in mature and emerging markets. With 22 years of experience in Novartis, he successfully developed, launched, and expanded primary care and
specialty medicines across various therapeutic areas.
Dr. Beat joined Sanofi, Paris as Global Head of Medical Operations & Effectiveness, SVP in 2017 and later moved to Galderma, Switzerland as a Global Head for Medical
Excellence & Operations. Throughout his career as a Medical leader, he established and led impactful and highly efficient medical organizations (global, regional and local)
and pioneered the integration of digital technology & AI in engagement strategies.
Dr. Beat Sümegi holds an Executive master’s degree in business administration from Concordia University, Faculty of Commerce, John Molson School of Business,
Montréal, Canada, and a Medical Doctor’s degree from University of Vienna, Faculty of Medicine, Vienna, Austria. He is a certified Physician in Austria and EU,
Switzerland, and South Africa.
We at Wellesta start our foot print in Europe with appointment of Dr Beat , who will lead work in areas of In Licencing, Out licensing & also Business development
work for IntelliMedEsta, our medical services arm. We are sure that Dr. Beat Sümegi’s experience and leadership will help achieve our vision and mission in Europe.
He will report to Mr. Milan Paleja, Chairman and MD of Wellesta Group.
We welcome Dr. Beat Sumegi to the Wellesta family and wish him great success in this new position.
We are pleased to announce the appointment of Mr. Venkatesan Karaiyalan as Head of Finance for India Business and
Financial Process Excellence Lead for Wellesta Group of Companies.
Effective from 15th Jan 2024
Mr. Venkatesan Karaiyalan has been appointed as Head of Finance for Wellesta Healthcare Pvt. Ltd., India and Financial
Process Excellence Lead for Wellesta Group in areas like enrichment of Technical Accounting Principles and System Lead.
He is a Business-Finance Leader with multi-faceted experience in Top Global & Indian Organisations like Novartis,
Danaher Corporation, CMA CGM, Sresta - 24 Mantra.
Prior to joining Wellesta, Mr. Karaiyalan worked as Chief Financial Officer at Sresta Natural Bio Products Pvt. Ltd. (24
Mantra) where he guided Business Strategy & Performance, monitored Financial Performance, Working capital, Cash-flows ,
Compliances and P&L growth.
His career spans over 28 years with comprehensive experience in various leadership roles and headed multi-locational
Operations in diverse verticals like FMCG, Pharmaceuticals, Medical Devices, Test & Measuring Equipments, Global Captive
Logistics BPOs, Consumer Durables.
He comes with extensive experience in Business Accounting, FP&A (Financial Planning & Analysis), Treasury, Taxation,
Risk Mitigation, Governance & Compliance, Cross-Functional Team Leadership & Stakeholder Management. He brings a
holistic view of Businesses and Strong Business Ethics.
Mr. Venkatesan Karaiyalan is a Chartered Accountant (ICAI- India) and holds a Master of Commerce degree from Madurai
Kamaraj University, Tamil Nadu.
We see good opportunities in Indian Healthcare markets and opportunities for Wellesta to grow and show strong progress.
We are sure that Mr. Venkatesan Karaiyalan’s experience will help our India business plan to achieve our vision and
mission in India. He will report to Mr. Ashish Srivastava, Country Head, Wellesta India.
We welcome Mr. Venkatesan Karaiyalan to our Wellesta family and wish him great success in his new position.
We are pleased to announce the appointment of Mr. Ashish Srivastava as Country Head for India business & to Wellesta
India BOD with effect from 15th January, 2024.
Effective from 15th Jan 2024
Mr. Ashish Srivastava has been appointed as Country Head for India business and also to the Wellesta India Board of
Directors with effect from January 15th, 2024.
Ashish is a seasoned player with extensive experience of 27 years in building brands, turning around & scaling up
businesses. Prior to joining Wellesta, he was a Global Head for Orthopaedic Business for Biotech Healthcare Limited.
Ashish started his career with Johnson & Johnson and was associated with organisations like Allergan, Becton Dickinson,
Intas Pharmaceuticals & Zydus Healthcare. He worked as Business Head (Ophthalmology) for Zydus Healthcare before he
forayed in International Operations with Biotech Healthcare Limited. His core experience has been in Medical Devices,
Ophthalmology & Orthopaedics lately.
Ashish holds Honours degree in Botanical Sciences from Delhi University and PGDBM from MDI, Gurgaon along with a
two-year Executive course from IIM Ahmedabad.
We at Wellesta are very optimistic about Indian Healthcare market & opportunities for Wellesta to progress. We are sure
that Ashish’s experience and leadership will help achieve our vision and mission in India. He will report to Milan
Paleja, Chairman and MD of Wellesta Group.
We welcome Mr. Ashish Srivastava to the Wellesta family and wish him great success in this new position.
We are pleased to announce our strategic partnership with BioCheetah for commercializing VECanDx™ ELISA test for early
detection of bladder cancer.
Effective from 26th Sept 2023
Wellesta and BioCheetah have signed an agreement whereby Wellesta will be commercializing BioCheetah’s unique, patented
and biomarker-based test kit, VECanDx™ ELISA test for early detection of bladder cancer. This product will be sold,
marketed and distributed in ASEAN, Indian sub-continent, MENA, EU and LATAM.
BioCheetah’s VECanDx™ ELISA test is a non-invasive test used to detect bladder cancer in hematuria patients and
high-risk individuals. This Enzyme-linked immunosorbent assay (ELISA) test is a standard procedure which are
well-established in hospitals and laboratories to detect five specific patented protein biomarkers that are present in
bladder cancer.
Bladder cancer incidence rate is growing every year and further worsening with other lifestyle habits and issues such as
obesity, diabetes and smoking. Thus, this strategic move will help the patients with early-stage screening of bladder
cancer, support the medical community by bringing efficient, robust and good quality screening tool in the market.
While talking about this partnership, Dr. Kian-Chung Lee, CEO and co-Founder of BioCheetah said, “We are happy to join
hands with Wellesta to commercialise VECanDx™ ELISA test kit to provide high sensitivity and specificity for diagnosis
and monitoring of bladder cancer through urine-based biomarkers panel. With a fast-growing company like Wellesta, we are
definite to achieve our goal to provide access to early cancer detection technology to many larger territories.”
The Chairman and MD of Wellesta, Mr. Milan Paleja added, “BioCheetah’s bladder cancer detection kit offers affordable
and accurate detection of bladder cancer for early treatment. This aligns with Wellesta’s objective to provide high
quality, right priced innovative products for better patient outcomes. We would be commercializing this product country
by country, in ASEAN, Indian sub-continent, MENA, EU and LATAM countries.”
BioCheetah also has products in pipeline which are under development and will be available for commercialization once
developed.
About Wellesta:
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market presence in Southeast
Asia & India and partnering in MENA. We aim to serve clients and consumers through commercial and marketing support
using an innovative approach across the Wellesta value chain. We work with companies to expand their presence in
Southeast Asia & India as a strategic partner for companies present in these markets and act as a representative for
companies that are not present in these markets and would like to sell/market their products in the region.
Wellesta Holdings operate in a spectrum of business verticals under partner brands and own brands including
pharmaceutical, nutraceuticals, OTC and medical devices, led by industry-proven leaders at HQ & Country level. Wellesta
works as an extended arm for our principals through win-win partnership and provides superior quality products and
services at the right price, by working at full compliance and transparency in our business approach.
BioCheetah Private Limited, is a Singapore-based start-up diagnostics company set up to develop and commercialize
non-invasive, protein-based immunodiagnostic applications. We are a company using patented bladder cancer biomarkers and
detection antibodies for development of in-vitro diagnostic ELISA and Point-of-care test (POCT) kits for urological
cancers. BioCheetah currently has an ISO13485 pilot production facility in Singapore for the purpose of development and
small-scale manufacturing of its diagnostic products. Our goal is to manufacture diagnostics kits to allow healthcare
providers to triage patients using our products with fast turnaround, exceptional quality, and competitive pricing via
novel biomarkers for the diagnosis and recurrence monitoring of bladder cancer and other urological cancers.
The company is currently running clinical trials worldwide with hospitals in Singapore, China and France and anticipate
the completion of these trials in Quarter 4 2023, before applying for Singapore’s Health Sciences Authority and US FDA
510(k) product registry in Q1 2024.
We are pleased to announce Advanced Chemicals Industries (ACI) Pharma as our strategic partner for Bangladesh market.
Effective from 27th Oct 2023
Wellesta Holdings and Advanced Chemicals Industries (ACI) Pharma have entered into sales and
marketing agreement for FathomX, BioCheetah, Butterfly & SKIIP for Bangladesh market. Through this collaboration, these
highly innovative products will be available in the market to enhance the healthcare scenarios in Bangladesh.
FathomX is an Artificial Intelligence powered breast cancer detection software that enables quicker and more accurate
diagnosis for breast cancer in merely minutes.
BioCheetah’s VECanDx™ ELISA test is a unique, patented and biomarker-based test kit for early detection of bladder
cancer for better management of treatment.
Butterfly is an innovative and world’s first single probe, whole body handheld POCUS – Point of Care Ultrasound solution
for advanced Medical Imaging.
SKIIP is a highly effective smoking cessation product that helps smokers successfully wean off their nicotine addiction
in 12 weeks.
While talking about this collaboration, M Mohibuz Zaman, MD & CEO, ACI Healthcare Ltd. said, “I am extremely happy to
partner with Wellesta in bringing unique, patented and high-quality healthcare products in Bangladesh. Together we are
dedicated to creating a healthier and more accessible technology-led healthcare system in Bangladesh.”
Mr. Milan Paleja, MD and Chairman of Wellesta added about this collaboration, “This strategic partnership with ACI will
help the patients, society and medical community of Bangladesh with innovative, high quality healthcare solutions at
right price. With such innovative products we aim to enhance the lives of people in Bangladesh. We are honoured to have
such a forward-looking partner in our journey and will continue to expand the collaboration with ACI Pharma for bringing
many more innovative healthcare products in coming periods, to the country.”
In addition, both Companies share their gratitude to Mitsui & Co. (Asia Pacific) Pte. Ltd.
as the company play an important role to this collaboration between ACI and Wellesta.
About Wellesta:
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market presence in Southeast
Asia & India and partnering in MENA. We aim to serve clients and consumers through commercial and marketing support
using an innovative approach across the Wellesta value chain. We work with companies to expand their presence in
Southeast Asia & India as a strategic partner for companies present in these markets and act as a representative for
companies that are not present in these markets and would like to sell/market their products in the region.
Wellesta Holdings operate in a spectrum of business verticals under partner brands and own brands including
pharmaceutical, nutraceuticals, OTC and medical devices, led by industry-proven leaders at HQ & Country level. Wellesta
works as an extended arm for our principals through win-win partnership and provides superior quality products and
services at the right price, by working at full compliance and transparency in our business approach.
Advanced Chemical Industries (ACI) Limited, being one of the largest conglomerates in Bangladesh with a multinational
heritage operates across the country through its four diversified strategic business units. ‘ACI Pharmaceuticals’ is
dedicated to improving the health of the people of Bangladesh through introduction of innovative and reliable
Pharmaceuticals products. Very recently, ACI Limited introduced a new business venture (Healthcare Equipment) under its
pharmaceuticals division with a view to developing healthcare eco-system in Bangladesh.
With almost three decades of partnering life and engendering hope, ACI is one of the top pharmaceutical companies in
Bangladesh, employing more than 6,000 people all over the country. As a progressive and forward-thinking company, ACI's
Mission is to enrich the quality of life of the people through responsible application of knowledge, technology and
skills. ACI is committed to the pursuit of excellence through world-class products, innovative processes and empowered
employees, to provide the highest level of satisfaction to our customers.
We are excited to announce Ancom Truelife as our distribution partner in Malaysia for Fx Mammo, a new Artificial
Intelligence (AI) powered breast cancer detection software
Effective from 20th Oct 2023
Wellesta Holdings Pte Ltd announces Ancom Truelife, a healthcare solution provider in Malaysia, as its Distribution
partner for selling and marketing Fx Mammo, an AI-based breast cancer detection software, in the government healthcare
institutions in Malaysia. This is AI powered breast cancer detection software will enable quicker and more accurate
diagnosis for breast cancer in Malaysian women, in merely minutes.
Wellesta Holdings Pte Ltd, a healthcare company headquartered in Singapore and Ancom Truelife based in Malaysia, will
jointly sell and market this game-changing technology in the private sector of Malaysia. This will be done through
active demand generation and building patient awareness about early detection being the most critical aspect for curbing
breast cancer related deaths, as early detection help with early treatment.
While talking about this collaboration, Datuk Siew Ka Wei, Ancom Truelife Director said, “The introduction of Fx Mammo
marks a significant step towards creating a healthier and more accessible healthcare system in Malaysia, one that
leverages the power of AI to make a lasting impact on the fight against breast cancer.”
Mr. Milan Paleja, Chairman & MD Wellesta added about this collaboration that Fx Mammo is a powerful AI tool for early
diagnosis of breast cancer as it is set to revolutionize the way radiologists analyse mammograms, ultimately improving
health and lives of Malaysian women.
Ancom Truelife specializes in people-first healthcare solutions which aligns with Wellesta’s objectives. Hence this
significant partnership is a step forward to a common vision of improving scenarios of cancer detection in Malaysia.
We are pleased to announce the appointment of Ms. Serene Ng as Regional Project Manager, Pharma for Wellesta.
Effective from 17th July 2023
We are pleased to announce the appointment of Ms. Serene Ng as Regional Project Manager, Pharma for
Wellesta w.e.f. 17th
July, 2023. Prior to joining Wellesta, Ms. Serene worked as Regional Manager at Medochemie responsible for SEA,
Hong
Kong, Macau and Taiwan’s overall business. She is a seasoned commercial leader with over 20 years of experience
within
the pharmaceutical industry.
Ms. Serene Ng started her career in 2000 as Product Specialist and worked in different companies – Roche,
Sanofi & Eli
Lilly until 2006. She joined Merck (M) Sdn. Bhd. as a Product Manager for Oncology department to cover the
Malaysia
region. In September 2011, she became the Business Unit Manager at Merck Pte Ltd and was responsible for
Singapore &
Brunei’s Oncology business sales performance and P&L. She then joined Astellas Pharma Pte Ltd as Senior Manager,
Marketing (Head of Marketing) and covered Singapore, Brunei, Malaysia and Vietnam regions. She rose in rank to
become
the Regional Marketing Director in Astellas Pharma Pte Ltd and was responsible for overall company portfolio –
Immunology, Oncology, Urology, Infectious disease & Gout marketing strategies, performance and profitability in
SEA and
South Asia.
In April 2018, she was appointed as the Country Manager for Astellas Pharma Sdn Bhd, to grow Malaysia
affiliate into a
high-performing business and building the company brand among the healthcare industry. She then joined Glenmark
Pharmaceutical as a Country Manager for Malaysia, Singapore and Brunei in December 2020 and worked for 2 years
to lead a
team of Sales & Marketing, Commercial Excellence, Supply Chain, HR, Finance, Medical Affairs and Regulatory
Affairs/PV;
headcount of 56 employees based in Malaysia region.
Ms. Serene Ng holds a Bachelor of Business Administration (Marketing) from Oklahoma State University,
Stillwater,
Oklahoma U.S.A. and Master of Business Administration from Lincoln University, U.K.
We at Wellesta see good opportunities in SEA & Indian Healthcare markets and opportunities for Wellesta to
progress. We
are sure that Ms. Serene’s rich experience and leadership will help us achieve our vision and mission. She will
report
to Milan Paleja, Chairman and MD of Wellesta Group.
We welcome Ms. Serene Ng to the Wellesta family and wish her great success in her new position.
We are pleased to announce the appointment of Ms. Anisha Ramkorun as Accounting Manager for Wellesta.
Effective from 30th June 2023
We are pleased to announce the appointment of Ms. Anisha Ramkorun as Accounting Manager for Wellesta
w.e.f. 30th June,
2023. Prior to joining Wellesta, Ms. Anisha worked as Senior Finance Analyst at Johnson & Johnson. She has an
experience
of 12 years in the field of Accounts and Finance with strong business acumen and GAAP knowledge.
Ms. Anisha Ramkorun started her career in 2008 as Business Risk Associate (Internal Auditor) and worked for
over two
years. Later she worked as Finance Executive at Starhub, a Telecommunication Company until October 2011. She
joined
Caterpillar Asia as Accounts Analyst in 2012 where she administered the corporate credit card program for more
than 1000
employees and managed the expense report reimbursement program for travelers in Singapore & Australia. In March
2016,
she joined ISS Consulting Pte Ltd as a Finance Executive and managed business performance; Reporting & Variance
analysis.
From August 2017, she rose in rank to work as a Finance Analyst for VISA and managed the CEMEA region. She
continued to
work as a Finance Analyst at Techlyon Pte Ltd from June 2021 to August 2022 before joining Johnson & Johnson as
Senior
Finance Analyst. She collaborates effectively with business managers to resolve variances, refine forecasts and
identify
opportunities for improvement.
Ms. Anisha is a Chartered Accountant (CA- Singapore) and holds a bachelor’s in Accounting & Finance degree
from
University of London, Singapore as well as a Diploma in Management Studies from Singapore Institute of
Management.
We at Wellesta see good opportunities in SEA & Indian Healthcare markets and opportunities for Wellesta to
progress. We
are sure that Ms. Anisha Ramkorun’s rich experience will help us achieve our vision and mission. She will report
to
Milan Paleja, Chairman and MD of Wellesta Group.
We welcome Ms. Anisha Ramkorun to our Wellesta family and wish her great success in her new position.
We are pleased to announce the appointment of Ms. Soyoka Yoshimi as Project Manager,
Pharmaceuticals for Wellesta.
Effective from 12th June 2023
We are pleased to announce the appointment of Ms. Soyoka Yoshimi as Project Manager -
Pharmaceuticals, for Wellesta w.e.f. 12 th June, 2023.
Prior to joining Wellesta, Ms. Soyoka
worked as Project Manager, Global Healthcare Solution Department, Healthcare Business
Unit at Mitsui & Co., Ltd., Tokyo Japan. Here she was appointed as Director for MBK
Pharmapartnering Inc. (MBKPP), Delaware (Mitsui’s investment vehicle for Nova Quest). She
has rich experience in the pharmaceutical industry and exposure to various
businesses/projects including API trading, licensing deals, fund management, share
transfer/business transfer, etc.
Ms. Soyoka started her career in 2017 as Physical Therapist at Ito Clinic. She joined Mitsui &
Co., Ltd in 2019 as staff for Global Supply Chain Management Dept. in Pharmaceutical
division and was then appointed as Project Manager of Global Healthcare Solutions
Department where she supports the growth of Fuji Pharma Co. Ltd., a Japanese
pharmaceutical company specializing in Women’s Health.
From March 2022, she rose in rank as Project Manager in Mitsui’s Global Healthcare
Solutions Department to lead in making business forecasts and department’s mid-term plan.
She was appointed as Accounting Manager for MBK Provider Network (MBKPN) and Cayman
(Mitsui’s investment vehicle for Columbia Asia Healthcare; CLA) to lead negotiations for
Mitsui’s divestment of CLA and its execution.
Ms. Soyoka will support Wellesta’s business development, mainly with, but not limited to
Japanese Pharmaceutical companies. Her role will include seeking potential collaboration
opportunities with the portfolio companies of Mitsui & Co. Ltd.
Ms. Soyoka has 6-years education in the medical field with 11 Publications in women’s
health and musculoskeletal assessment. She holds a Masters in Medical Science and
Bachelors degree in Human Health Sciences, Physical Therapy from Kyoto University, Japan.
We at Wellesta see good opportunities in SEA & Indian Healthcare markets and
opportunities for Wellesta to progress. We are sure that Ms. Soyoka Yoshimi’s rich
experience and leadership will help us achieve our vision and mission. She will report to
Milan Paleja, Chairman and MD of Wellesta Group.
We welcome Ms. Soyoka Yoshimi to our Wellesta family and wish her great success in her
new position.
Wellesta announces Mitsui & Co., Ltd and Japan Bank for International Cooperation (JBIC) as Series B Investors
in the company. This Investment round will help Wellesta for its strategic growth initiatives & geographical
expansion.
Effective from 6th April 2023.
Wellesta, today announced a joint investment in the company from Mitsui & Co., Ltd and Japan Bank for
International Cooperation, known as JBIC.
Mitsui & Co., Ltd is a global company with a diversified portfolio of trading, investment and business
activities across various industries and JBIC is a policy-based financial institution and conducts loans,
guarantees and equity participations. Wellesta is a Healthcare Company based from Singapore and have set up to
provide marketing and commercial support in SEA and India & partnering in MENA with a team of well qualified,
experienced and industry proven leaders.
Wellesta, since the time of its inception has achieved footprints in 6 countries, partnership in MENA in terms
of commercial operations and plans to enter the manufacturing vertical to tap the business opportunities in
specific geographies.
Wellesta’s mission is to provide wider range, high quality and right priced healthcare products to
population base in the countries of operation from its Principal’s and Innovators across the world.
Mitsui, an investor in Wellesta has a vision to support improvement of people’s health and wellness
through provision of Value Based Healthcare.
JBIC, an investor in Wellesta has a mission to contribute to the sound development of Japan and the
international economy and society.
The investment of Mitsui & JBIC in Wellesta will help the Wellesta business initiatives and support its
Vision and Mission.
With this new relationship, Mr. Milan Paleja, Chairman & MD, Wellesta said “I am extremely delighted and
thankful for Mitsui & JBIC who have posed confidence in our organization and being our strategic long-term
partner. The investment from them will help us achieve our strategic plan which is being rolled out in SEA,
India and also partner in MENA.
Mr. Takeshi Akutsu, the Managing Officer & Chief Operating Officer of Wellness Business Unit at Mitsui & Co.,
Ltd, said “We believe that enhancing access to quality drugs and solving so-called ‘drug-lag’ issue are very
important for health and wellness of people, especially people living in emerging countries where Wellesta
deploys its operations. We are very grateful and excited to have the opportunity to invest in Wellesta as a
strategic partner together with JBIC, as we can fully share the above mission with Mr. Milan Paleja.
We are confident that Wellesta's Industry Knowledge, Network and sales and marketing capabilities for healthcare
products will be the perfect solution for global manufacturers, as well as for healthcare startups, who want to
bring their innovative products to the medical communities and patients in Asia. Leveraging Mitsui’s global
network, we will be committed to contribute to Wellesta’s further geographical expansions in the emerging
markets and would like to introduce various excellent products from all over the world to Wellesta and
contribute to the health and wellness of the people living there.”
Mr. Paleja explained that new Strategic Investment will help Wellesta mainly in areas of:
Growth working capital
Investment in launches of New products, Devices and Diagnostic with right price access.
New Footprints; Further Geographical Expansions and potential Investment in Manufacturing units in
strategic markets.
Network of Mitsui portfolio companies will help Wellesta in Business & Access.
About Wellesta:
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market presence in
Southeast Asia & India and partnering in MENA. We aim to serve clients and consumers through commercial and
marketing support using an innovative approach across the Wellesta value chain. We work with companies to expand
their presence in Southeast Asia & India as a strategic partner for companies present in these markets and act
as a representative for companies that are not present in these markets and would like to sell/market their
products in the region.
Wellesta Holdings operate in a spectrum of business verticals under our partner brands and own brands including
pharmaceutical, nutraceuticals, OTC and medical devices, led by industry-proven leaders at HQ & Country level.
Wellesta works as an extended arm for our principals through win-win partnership and provides superior quality
products and services at the right price, by working at full compliance and transparency in our business
approach. This joint collaboration supports the mission of Wellesta to provide cost-effective and high-quality
products and services and help to deliver better patient outcomes in healthcare.
About Mitsui & Co., Ltd:
Mitsui & Co., Ltd. (8031: JP) is a global trading and investment company with a diversified business portfolio
that spans approximately 63 countries in Asia, Europe, North, Central & South America, The Middle East, Africa
and Oceania.
Mitsui has about 5,500 employees and deploys talent around the globe to identify, develop, and grow businesses
in collaboration with a global network of trusted partners. Mitsui has built a strong and diverse core business
portfolio covering the Mineral and Metal Resources, Energy, Machinery and Infrastructure, and Chemicals
industries.
Leveraging its strengths, Mitsui has further diversified beyond its core profit pillars to create multifaceted
value in new areas, including innovative Energy Solutions, Healthcare & Nutrition and through a strategic focus
on high-growth Asian markets. This strategy aims to derive growth opportunities by harnessing some of the
world’s main mega-trends: sustainability, health & wellness, digitalization and the growing power of the
consumer.
Mitsui has a long heritage in Asia, where it has established a diverse and strategic portfolio of businesses and
partners that gives it a strong differentiating edge, provides exceptional access for all global partners to the
world’s fastest growing region and strengthens its international portfolio.
For more information on Mitsui & Co’s businesses visit, www.mitsui.com and follow us on LinkedIn.
About Japan Bank for International Cooperation（JBIC)
JBIC is a Japanese policy-based financial institution wholly owned by the Government of Japan, which has the
objective of contributing to the sound development of Japan and the international economy and society by
conducting financial operations.
Its financial operations cover loans, guarantees and equity participations. Under the Fourth Medium-term
Business Plan (FY2021-FY2023) formulated in June 2021, JBIC has set priority targets that include realizing the
SDGs, decarbonization, energy transformation, and digital transformation as it aims to fulfill its mandates
steadily and flexibly. JBIC, under the objective and priority targets, supported projects and companies across
various sectors such as power, infrastructure, natural resources and environment.
We are pleased to announce the appointment of Ms. Chang Shen Yun as Regional IT Manager for Wellesta w.e.f. 20th
February 2023.
Effective from 20th February 2023
We are pleased to announce the appointment of Ms. Chang Shen Yun as Regional IT Manager for Wellesta
w.e.f. 20th
February 2023. Prior to joining Wellesta, Ms. Shen worked with Robert Bosch Sdn Bhd, Malaysia as an IT Manager &
Head of
Department. Her IT experience spans over 24 years in IT industry with specialization in IT infrastructure & IT
operations.
Ms. Chang Shen Yun started her career in 1994 as an Analyst Programmer and then joined Electroscons
Telecommunication in
1996 as a MIS Executive for 3 years. She then rose in rank to work as an IT Assistant Manager at Johnson Control
Automotive Holding (M) Sdn Bhd, an automobile company. In her tenure of 10 years there, she executed all aspects
of
Strategic IT planning & budgeting, participated in implementation, maintenance and support of Corporate
Application
Systems for assigned business area & ensured system security, developed and maintained back-up and disaster
recovery
plans and procedures.
In 2010, she took up a senior role and worked as an IT Manager & Head of Department at Robert Bosch Sdn
Bhd, a
multinational engineering & technology company headquartered in Geringen, Germany. She was associated with them
for 12
years and played a local management and ASEAN regional roles. She led the department in providing daily IT
support,
acted as an IT Business Partner to execute/monitor all aspects of IT planning and budget, ensured continuous
uptime of
network connection, data and communication infrastructure for business continuity in 2 legal entities and 2
warehouses.
For ASEAN regional role, she was actively involved in Objective Key Results (OKRs) activities to ensure
operational
excellence and provided all the IT Service Management updates.
Ms. Shen is a science degree graduate majoring in Computer Science from Campbell University of North
Carolina, USA &
holds Certificate in Computer Studies from Tunku Abdul Rahman College, Kuala Lumpur, Malaysia.
We are sure that Ms. Shen’s experience and leadership will help us achieve our vision and mission, and
establish more
stronger IT base for Wellesta. Ms. Chang Shen Yun will be based out of Malaysia and will report to Milan Paleja,
Chairman and MD of Wellesta Group.
We welcome Ms. Chang Shen Yun to the Wellesta family and wish her great success in her new position.
We are pleased to announce the appointment of Ms. Pearleen Tan Ching Yen as Regional
Marketing Head, DTC for Wellesta w.e.f. 17th April 2023.
Effective from 17th April 2023
We are pleased to announce the appointment of Ms. Pearleen Tan as Regional Marketing
Head – Direct to Consumer, for Wellesta w.e.f. 17th April 2023. Prior to joining
Wellesta, Ms. Pearleen Tan worked as Head of Marketing for India & SEA at Hillrom,
Singapore which is now a part of Baxter. She is a true Marketing leader with over 20 years of
experience and global exposure in Marketing and Distributor Sales Management.
Starting her sales and marketing career in the FMCG and Nutrition industry with
Frieslandcampina in 2001, Ms. Pearleen Tan landed in her first regional role joining Novartis - Infant and Baby
division (GERBER) in 2005 as Sales and Marketing Manager for Singapore,
Malaysia and Pacific Islands and rose in rank to Head of Marketing for Asia, Middle East,
North Africa Region for Novartis - Ciba Vision. Further to this, she had taken on pivotal roles
with Philips HealthCare and Cardinal Health Pte Ltd to drive market entry strategies and
marketing innovations for the Asia Pacific region. In 2019, after joining ResMed as a Go -To-
Market Lead for Emerging Asia team, she successfully led the business continuity initiative,
Korea commercial and marketing teams in Emerging Asia to achieve a 33% increase in
overall region full-year revenue growth and a 9.5% improved revenue for sleep portfolio
despite COVID-19. She was promoted from Go-to-Market Lead to Director, Group Solutions
Marketing to lead the Emerging Asia Solutions Group in orchestrating aggressive end-to-
end commercial solutions tailored towards the omni-channel eco-system of customers in
2020.
Ms. Pearleen Tan holds a Bachelor and Master of Business degree from Queensland
University of Technology, Australia.
We at Wellesta see good opportunities in SEA & Indian Healthcare markets and
opportunities for Wellesta to progress. We are sure that Ms. Pearleen Tan's rich experience
and leadership will help us achieve our vision and missionmissio. She will report to Milan
Paleja, Chairman and MD of Wellesta Group.
We welcome Ms. Pearleen Tan to the Wellesta family and wish her great success in her new
position.
We are pleased to announce the appointment of Ms. Angela Tham as Regional Marketing Manager for Wellesta,
Singapore w.e.f. 25th October 2021.
Effective from 25th October 2021
Prior to joining Wellesta, Ms. Angela worked with A. Menarini as a Senior Product Manager. Her marketing
experience spans over 8 years of handling both local and regional portfolios in Singapore and across the
Southeast Asia region in the pharmaceutical industry in multiple therapeutic areas such as Gynaecology,
Obstetrics, Dermatology, Aesthetics, ENT, Urology, Men’s Health & Gastroenterology.
Ms. Angela Tham started her career as a Product Executive for Hyphens Pharma in 2009 and rose to ranks in 2013
as an Assistant Manager role handling market development for 2 years where she started to get involved in the
Indonesia Market. With her personal and working experience in both sales and marketing, she started mentoring
and supporting both the Singapore team as a Product Manager and the Indonesia sales team in opening new
opportunities.
In 2016, she was promoted to Associate Regional Product Manager which expanded her coverage across Hyphens
regional offices in Singapore, Malaysia, Indonesia, Philippines and Vietnam focusing on the Dermatology business
unit. She is well experienced in handling new product launches, organizing regional symposiums and working on
new product developments. She has also been involved in clinical studies conducted across the region, working
with various societies and hospital departments.
With her drive to pursue an all-rounded career, Ms. Angela Tham decided to move to A. Menarini Singapore in 2019
as a Senior Product Manager. In her 2 years with Menarini, she was mainly involved in launching 3 new brands
including the product development of an anti-aging cosmetic range, working on formulation, branding and
packaging design.
Ms. Angela Tham is a science degree graduate majoring in Biomedical Science and Microbiology from the University
of Queensland, Australia.
We are very sure that Angela’s experience locally & SEA will help our business growth agenda. Ms. Angela will
report to Milan Paleja, Chairman and MD of the Wellesta Group.
We welcome Ms. Angela to the Wellesta family and wish her great success in her new position.
Wellesta Holdings Pte Ltd is pleased to announce a collaboration
with Altamira Therapeutics to market and distribute Bentrio in Six Key Asian
Markets
Wellesta Holdings Pte Ltd and Altamira Therapeutics Ltd. have signed a letter of
understanding (“LOU”) for the marketing and distribution of Bentrio™ in India, Indonesia,
Malaysia, Singapore, Taiwan and Vietnam. Bentrio™ is a nasal spray for protection against
airborne viruses and allergens. Wellesta will register Bentrio™ in the respective countries
and start promoting and selling the product in those markets. In Singapore, Bentrio
is classified as a Class A medical
device.
Wellesta Holdings Pte Ltd is a Healthcare Company headquartered in Singapore, and
Altamira Therapeutics Ltd. is headquartered in Hamilton, Bermuda with its main operations
in Basel, Switzerland. This collaboration will offer greater distribution of Bentrio™ to our
consumers in the Asia-Pacific region.
Bentrio™ is a drug-free nasal spray intended for personal protection against airborne viruses
and allergens. Upon application in the nose, Bentrio™ forms a protective gel layer on the
nasal mucosa. It is designed to reduce the risk of upper respiratory tract viral infections and
promote alleviation of allergic symptoms.
While talking about this collaboration, Mr. Thomas Meyer, Chairman, CEO and founder of
Altamira Therapeutics, said: “Wellesta has achieved rapid growth and great success in
building a high-quality portfolio of health care products for distribution in South East Asia
and India, and we very much look forward to working with its team.”
While talking about collaboration, Mr. Milan Paleja, Chairman & MD of Wellesta, said that
his company is very excited to partner with Altamira to market Bentrio™, which is already
on the market in several big EU countries, to help protect people against airborne viruses
and allergens in 6 important countries across Asia.
Mr. Paleja also thanked deal advisors, AAA consulting, to help support this transaction.
About Wellesta Holdings
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct
market presence in Southeast Asia & India and partnering in MENA. We aim to serve clients
and consumers through commercial and marketing support using an innovative approach
across the Wellesta value chain. We work with companies to expand their presence in SEA &
India as a strategic partner for companies present in these markets and act as a
representative for companies that are not present in these markets and would like to
sell/market their products in the region.
Wellesta Holdings operates in a spectrum of business verticals under our Partner Brands and
Own Brands including Pharmaceutical, Nutraceuticals, OTC and Medical devices, which is
being led by industry-proven leaders at HQ & country level. Wellesta works as an extended
arm for principals through win-win partnership and provide superior quality products and
services at the right price, by working at full compliance and transparency in our business
approach. This joint collaboration supports the mission of Wellesta to provide cost-effective
and high-quality products and services and help to deliver better patient outcomes in
healthcare.
About Altamira Therapeutics
Altamira Therapeutics is dedicated to developing therapeutics that address important
unmet medical needs. The Company is currently active in three areas: The development of
RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™
platforms; preclinical), nasal sprays for protection against airborne viruses and allergens
(Bentrio™; commercial) or the treatment of vertigo (AM-125; Phase 2), and the
development of therapeutics for intratympanic treatment of tinnitus or hearing loss
(Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in 2003 and is headquartered
in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira
Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”
Wellesta Holdings Pte Ltd is pleased to broaden collaboration with Altamira Therapeutics to market and
distribute Bentrio in two additional markets
Wellesta Holdings Pte Ltd and Altamira Therapeutics Ltd have broaden their agreement for marketing and
distribution of Bentrio™ by including two attractive new markets. In addition to India, Indonesia, Malaysia,
Singapore, Taiwan and Vietnam, Wellesta will also start promoting and selling Bentrio™ in Philippines & Morocco,
upon registration in these two countries.
Bentrio™ is a drug-free nasal spray intended for personal protection against airborne viruses and allergens.
Upon application in the nose, Bentrio™ forms a protective gel layer on the nasal mucosa. It is designed to
reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic
symptoms.
Wellesta has
successfully registered Bentrio
in Malaysia, whilst In Singapore,
Bentrio has been classified as a
Class A medical device, since the
signing of marketing & distribution agreement in October 2021, and is currently in process of obtaining
marketing clearance in other six countries covered by the agreement.
Mr. Milan Paleja, Chairman & MD of Wellesta is excited about extending benefits of Bentrio™ to additional
geographies and said “Happy to expand collaboration with Altamira Therapeutics to market and distribute Bentrio™
in Philippines and Morocco as well, which shows great potential for business and further help protect larger
masses against airborne viruses and allergens.”
About Wellesta Holdings
Wellesta Holdings Pte Ltd is a fast-growing healthcare company headquartered in Singapore with a direct market
presence in Southeast Asia, India & North Africa. The company aims to serve clients and consumers through
commercial and marketing support using an innovative approach across the Wellesta value chain.
Founded in 2019 by two executives with more than 70 years of cumulated experience in leading multinational
companies (MNCs) in health care, the company has since grown to more than 540 employees.
Wellesta works with companies to expand their presence in SEA, India & North Africa, as a strategic partner for
companies present in these markets and act as a representative for companies that are not present in these
markets and would like to sell/market their products in the region.
The company operates in a spectrum of business verticals under Partner Brands and Own Brands including
Pharmaceutical, Nutraceuticals, OTC and Medical devices, which is being led by industry-proven leaders at HQ &
country level. Wellesta works as an extended arm for principals through win-win partnership and provide superior
quality products and services at the right price, by working at full compliance and transparency in our business
approach.
About Altamira Therapeutics
Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The
Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic
targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses
and allergens (Bentrio™; commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of
therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). The
Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel,
Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol
“CYTO.”
Wellesta Holdings Pte. Ltd. is pleased & excited to announce an update on business development for the
Philippines: Wellesta will enter Philippine market through the purchase of a majority stake in Buergli Pharma
Inc.
Effective from 1st Nov 2021
Wellesta is a Healthcare company headquartered in Singapore with a direct market presence in South-east Asia,
India & North Africa and partnering in MENA. It supports the expansion of healthcare companies with its
specialisation in Marketing, Brand Management, Sales & Operations. It also acts as a launchpad for smaller
multinational corporations and biotech companies to venture into the Asia-Pacific region. Wellesta’s key focus
areas are Pharmaceuticals, Nutraceuticals, OTC and Medical devices and to support our principals’ products at
each stage of product life cycle.
Wellesta aims to be a valued partner to healthcare companies serving the community with a cost-effective &
expanded access product portfolio. Wellesta is led by industry-proven leaders at HQ & in each country, where it
is currently present.
Buergli Pharma Inc. has been operating in Philippines as an established Healthcare company for 15 years and is
also committed to providing affordable quality medicine and unique products to further develop and improve
healthcare outcomes in the Philippines and Southeast Asia. The company’s strong leadership brings together
seasoned pharmaceutical, OTC, and healthcare marketing professionals with relevant perspectives and strong,
solid ties to the healthcare industry in the Philippines.
This new company will be named Wellesta Buergli Pharma Inc. This partnership will facilitate Wellesta’s entry
into the Philippines’s market, launch current in-licensed products in Philippines as well as own brands.
Wellesta’s wider product range & larger geographic presence will also help Buergli to strengthen its current
portfolio. This will lead to win win partnership for both companies.
Ms. Carla Aquino has been appointed as Country Head of Wellesta Buergli & will lead the business for
Philippines. The announcement of Carla was made earlier on October 19th, 2021.
With the new combined business, we are confident of more employment in country and more development
opportunities to current employees. This will lead to larger and faster growing business for our current
employees & partners in Philippines.
We thank all who supported us in this transaction!
Milan Paleja
Chairman & MD, Wellesta
Reiner Gloor
President, Buergli Pharma
We are pleased to announce an update on business development for the Malaysian market:
Wellesta group in Malaysia will be merging business with the TrueLife group in Malaysia.
Effective from 6th Jan 2021
We are pleased to announce an update on business development for the Malaysian market: Wellesta group in
Malaysia will be merging business with the TrueLife group of Malaysia. The nutraceutical business will be
done by Wellesta TrueLife Sdn. Bhd. and the pharma business will be done by Wellesta Healthcare Sdn.
Bhd.
Wellesta is a company headquartered in Singapore which supports the expansion of healthcare companies
with its speciality in Marketing, Brand Management, and Sales & Operations. It also acts as a launchpad for
smaller multinational corporations and biotechnological companies to venture into Asia-Pacific. Being led
by industry-proven leaders, Wellesta aims to be a valued partner to healthcare companies serving the
community in Asia-Pacific with cost-effective and extensive pharmaceutical and healthcare products.
TrueLifeSciences is an established Malaysian company committed to producing supplements of the finest
quality with its innovative “Nutraceutical” range of products. With the company’s core strength in
innovation, technology and regulatory expertise, the company is focused on addressing the various needs for
disease prevention and treatment. TrueLifeScience’s mission is to empower and enrich lives by educating
and providing high quality health care products for the betterment of individuals.
The merger of the two companies in Malaysia accelerates business development for Wellesta into the
Malaysian market and similarly strengthens opportunities for TrueLifeSciences to venture into Asia-Pacific
and other countries where Wellesta operates directly and through partners. Additionally, the comprehensive
technological and communication structure of TrueLifeSciences supports Wellesta to draw further customer
and business networks. This merger aims to leverage on the opportunity to increase employment in the
market through such difficult times. It will hence be a union of the two companies to collaborate and achieve
their similar goals.
Both Wellesta and TrueLifeSciences focus on both the individual and the patients' well-being. With this,
Wellesta TrueLife’s mission to serve the people by providing quality and accessible healthcare products and
services at an optimum price will be achieved through this merger, which will be driven by our commitment,
in-market expertise, and efficient enactment.
We are pleased to announce the appointment of Ms. Carla Aquino as Country
Manager for Philippines for Wellesta w.e.f 18th October, 2021.
Effective from 18th Oct 2021
Prior to joining Wellesta, Carla was with AstraZeneca
Philippines as Business Unit Head and Head for the
Oncology Business Unit. She has extensive experience
with almost 19 years in the pharmaceutical industry, both
in consumer and ethical businesses, handling multiple
therapeutic areas such as Cardiovascular, Diabetes,
Neurology, Psychiatry, Respiratory and Oncology.
Ms. Carla Aquino started her career as Territory
Manager/Product Specialist for Roche Philippines, then
moved on from sales to marketing both in the OTC and Oncology businesses.
During her 10 years in Roche, she had regional assignment in Roche Hong Kong
Ltd. After Roche, she moved to GSK as Senior Product Manager for the CNS
Portfolio. As she continued to take on bigger roles, she moved to Boehringer
Ingelheim (BI) as Head of Specialty Business Unit. In BI, she handled Oncology and
Neurology while being the lead for market access and commercial excellence
initiatives. She played an integral role in launching and growing the Specialty
Business of BI.
Ms. Carla then moved to AstraZeneca as the Business Unit Head for the Oncology
Business Unit, where she was part of the Country Leadership Team. She had led the
team in coming up with various patient ecosystem solutions which gained various
awards both in AstraZeneca and externally, including multiple stakeholder
partnerships on early cancer diagnosis, artificial intelligence, and other patient
programs. She has rich experience on areas of talent development, high
performance culture, process simplifications, pilots, and innovations.
She holds a degree in BS Management Major in Communications Technology and
an MBA from the Ateneo de Manila University.
We at Wellesta see good growth opportunities in the Philippines Pharmaceutical &
Nutraceutical Markets. We are sure that Ms. Carla Aquino’s experience and
leadership will help achieve our vision and mission in the Philippines.
Ms. Carla Aquino will report to Milan Paleja, Chairman and MD of the Wellesta
Group.
We welcome Ms. Carla to Wellesta family and wish her all success & joy in her new
position.
We are pleased to announce the appointment of Ms. Prinka Mittal as Business
Development & Marketing Manager for Wellesta Holdings, Singapore & her appointment
is w.e.f. 16th August 2022.
Effective from 16th Aug 2022
Prior to joining Wellesta, Ms. Prinka worked with Naari Pharma (a Tenshi Group of
Lifesciences’ company) as Senior Manager, Business Development for other regulated
markets, emerging markets and global strategic accounts. Her career spans over 10 years of
comprehensive experience in International Business Development for regulated markets like
Europe, Australia & NZ, Canada and emerging markets. Ms. Prinka has handled multiple
roles in her previous assignments including project management, portfolio designing and
leading key launches in various markets under the larger role of business development.
She started her career from Strides Pharma as an executive in business development for
domestic division and moved on to international business development in subsequent roles.
She has also worked for a brief period at Biocon Ltd. as an International Marketing Executive
for API Division - APAC and South Africa markets.
Ms. Prinka Mittal pursued her B.Pharm and MBA from Narsee Monjee Institute of
Management Studies (NMIMS) Mumbai.
We are sure that Ms Mittal's rich experience and leadership will support us achieve our
vision and mission. She will report to Milan Paleja, Chairman and MD of the Wellesta Group.
We welcome Ms. Prinka Mittal to the Wellesta family and wish her great success.
We are pleased to announce the appointment of Mr. Ravinder Kumar Sagar as
CEO and Country Head for India with effect from Feb 1st 2021.
Effective from 1st Feb 2021
Mr. Ravinder Kumar Sagar has been appointed as CEO and Country Head of India with
effect from Feb 1st 2021. Mr. Sagar is a seasoned business leader with 39 years of experience,
and an ambitious visionary who believes in looking at problems as opportunities. He was
previously associated with Novartis for over three decades.
His experience spans over the entire country and has led businesses in specialties like
Transplant & Immunology, Oncology, Established brands business, Respiratory and most
recently with Key Accounts Management, which cuts across all the businesses of the
organization.
He started his career as a Medical Representative and rose to rank as Area Manager, Regional
Manager, Business Head, and also a member of the Pharma Executive Committee in his
journey with Novartis. He managed Sales, Marketing, Sales-Force Effectiveness, FF
deployment project post-merger in Novartis, Third-party FF, and Key Accounts
Management. KAM became the benchmark for not only Indian Pharma but also in the
AMEA (Asia, Middle East, Africa) region. He was the first-time recipient of the "Manager of
the Year" award in 2018, which was awarded by the regional head.
Mr. Sagar completed his MSc in Life Sciences from Panjabi University Patiala and Masters
in Marketing Management from NMIMS Mumbai.
We at Wellesta see good opportunities in Indian Healthcare Market, as well as ventures for
Wellesta to grow and make strong progress. We are sure that Mr. Sagar's experience and
leadership will help guide our India business plan to achieve our vision and missions in India.
Mr. Sagar will report to Milan Paleja, Director of Wellesta Healthcare India, and also the
Chairman and MD of the Wellesta Group.
We wish Mr. Ravinder Kumar Sagar great success in this new position.
We are pleased to announce the appointment of Mr. Ravinder Kumar Sagar as Senior Advisor to India Leadership
Team for India Business.
Effective from 15th Jul 2020
We are pleased to announce that Mr. Ravinder Kumar Sagar has been appointed as Senior Advisor to India
Leadership Team with effect from 15th July, 2020. Mr Sagar is a seasoned business leader with 39 years of
experience and a visionary who believes in looking at problems as opportunities and always aiming for slightly
impossible objectives. He was previously associated with Novartis for over 3 decades.
His experience spans over entire country and has lead businesses like Transplant & Immunology, Oncology,
Established brands business, Respiratory and more recently with Key Accounts Management which cuts across all
the businesses of the organization
His career started as Medical Rep, rose in to rank as Area Manager, Regional Manager, Business Head and member
of Pharma Executive Committee in his 3 decades journey with Novartis. He managed Sales, Marketing, SFE (Sales
Force Effectiveness), FF deployment project post- merger in Novartis, Third party FF and Key accounts
management. KAM became the benchmark for not only Indian Pharma but also in the AMEA region. He was awarded
“Manager of the year in 2018” by the regional head which was awarded for the first time to any individual in the
past.
Mr. Sagar completed his MSc in Life Sciences from Panjabi University Patiala and Masters in Marketing Management
from NMIMS Mumbai.
We at Wellesta are very optimistic about opportunities in Indian Healthcare Market & opportunities for Wellesta
to grow & make strong progress. We are sure that Mr. Sagar's experience & leadership will help our India
Business plan to achieve our Vision & Mission in India.
Mr. Sagar will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman &MD of the Wellesta
Group.
We welcome Mr. Ravi Kumar Sagar to our Wellesta family and wish him great success in this role.
We are pleased to announce our Strategic Business Alliance in India with Parazelsus through its subsidiary
company Wellesta
Healthcare Pvt. Ltd, India.
Effective from July, 2020
Wellesta Holdings Pte. Ltd is pleased to announce strategic alliance in India
with
Parazelsus through its subsidiary company in India,
Wellesta Healthcare Pvt. Ltd.
Parazelsus is an MNC company founded by
Peter Zuellig in 2007 and operates in multiple countries including India,
specializing in Distribution
& Logistics. The Company is led by
Markus Haefeli as Managing Director. Parazelsus India with its focus on
Distribution and Logistics
in the Healthcare sector, decided to partner with Wellesta in India for its CSO & Sales and Marketing business.
Wellesta’s core strength is Marketing, Brand Management, Sales & Operations with
world class standards in
its business approach and compliance. We foresee this partnership will make a Perfect Fit by offering an
end-to-end
business solution to business partners. With this decision 120 employees have moved from Parazelsus to Wellesta
in
India.
This will help us achieve our goal to provide high quality end to end professional services and support
while providing
high quality healthcare products at optimum prices, to support improving health for patients. Our focus would be
driven through our dedicated efforts, strong in-market experience, determination and commitment.
Strategic Alliance
Lunch post detailed business review meetings
Lunch with Leadership team of Strategic Alliance
We are pleased to announce the appointment of Mr. Kamal Anand as Director, Sales for Wellesta Healthcare Pvt.
Ltd, India.
Effective from 1st Dec 2019
Mr. Kamal Anand has been appointed Director, Sales for India business with effect from 1st December,
2019.
Mr. Anand is a competent professional with over 35 years of experience in Strategic Planning, Sales &
Marketing
and Business Development. In his last role, he was BU Head, Consumer Products Divison at Plethico
Pharmaceuticals
Ltd.
He possesses a strong leadership record and has a deep understanding of the consumer and business landscape
across
geographies having worked in the FMCG and Healthcare sector both in India and abroad. He started his career
after
his MBA as a Management Trainee in Ranbaxy, and later worked in DFM Foods, Dabur, Novartis and Plethico.
Mr. Anand holds an undergraduate and post graduate degree in Life Sciences as well as LLB degree from Delhi
University
and an MBA from Jodhpur University.
We at Wellesta are very optimistic about the opportunities in Indian Healthcare Market & opportunities
for Wellesta
to grow & make strong progress. We are sure that Mr. Anand's rich experience & leadership will help us
to
achieve our Vision & Mission in India.
Mr. Anand will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD
of the
Wellesta Group.
We welcome Mr. Kamal Anand, who is originally from Delhi and is now based in Mumbai, to our Wellesta
family. He
will lead Sales Organisation & be a part of India Leadership team.
We are pleased to announce the appointment of Mr. Sharad Virmani as Director, Partner Business for Wellesta
Healthcare Pvt.
Ltd.
Effective from 1st Feb 2020
Mr. Sharad Virmani has been appointed as Director, Partner Business for Wellesta Healthcare Pvt. Ltd with
effect from 1st February, 2020. Mr. Virmani is a very well-rounded professional with over 35 years of experience
in Pharma, Capital Equipment, Medical Devices, Diagnostics, Surgical & Healthcare in MNC & Indian
Companies.
In his last role, he was Country Head and Business Director - South Asia for Sales, Marketing & Contract
Sales
Operations at Parazelsus Pte Ltd.
His experience in business spans over Pan-India, Bangladesh and Nepal for both MNC’s and Indian Companies.
It encompasses
of setting up and managing Contract Sales Operations & New Business Divisions with exposure to handling
multiple
therapeutic segments.
His career started as a Medical Representative at Serdia and Hoechst (Sanofi) and later worked with
Torrent, AstraZeneca,
Nicholas Piramal, Micro – BAL, Pharmalink (Invida), Comed and Parazelsus.
Mr. Virmani is a Science Graduate from Kanpur University and has a Diploma in Export Management from Indian
Institute
of Export Management.
We at Wellesta are very optimistic about opportunities in the Indian Healthcare Market & opportunities
for Wellesta
to grow and make strong progress. We are sure that Mr. Virmani's rounded experience & leadership will help
to
achieve our Vision & Mission in India.
Mr. Virmani will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD
of the
Wellesta Group.
We welcome Mr. Sharad Virmani, originally from Delhi who is now based in Mumbai, to our Wellesta family and
we look
forward for him to make our company reach greater heights with his contribution.
Wellesta & Rubicon Research announce partnership to launch Nicotine Mini Lozenges in
Asia.
Rubicon Research Pvt Ltd and Wellesta Holdings Pte. Ltd enter into a licensing and supply
partnership to launch a highly effective nicotine lozenge that helps smokers to quit smoking. This
smoking cessation product helps smokers successfully wean off their nicotine addiction in 12 weeks
and helps them embark on a healthier journey of living cigarette-free.
Wellesta Holdings Pte. Ltd is a Healthcare Company headquartered in Singapore and Rubicon
Research is an Intellectual Property led Pharmaceutical Company based out of India, the US and
Canada. This partnership will offer an effective smoking cessation product to our consumers in
Asia.
The Nicotine Mini Lozenges are part of a 12-week therapy program, helping smokers gradually adjust
to having less nicotine till they no longer need any. The lozenges help relieve nicotine cravings and
alleviate withdrawal symptoms. The sugar-free lozenges are available in two strengths—2 mg and 4
mg—and come in a pack of 20 lozenges in 3 exciting flavors - Cherry, Cinnamon & Mint. Product will
be sold in Wellesta Brand name.
While talking about this unique product, Mr. Milan Paleja, Chairman and Managing Director of
Wellesta, said “With this collaboration we aim to help smokers quit the habit of Smoking and live
healthier life. We will launch this smoking cessation product in Singapore, Indonesia, Malaysia,
Philippines and Thailand and it will be sold under a Wellesta brand.”
Talking about the partnership, Parag Sancheti, Chief Executive Officer, Rubicon Research, said, “We
are excited to partner with Wellesta Holdings for the promotion and distribution of our products in
the Asia Pacific region. Finding the right partner who is aligned with our vision and core values is
important for us. Through this partnership we can leverage Wellesta’s powerful sales, marketing,
and distribution networks to provide an innovative product that helps people take charge of their
health.”
About Wellesta Holdings
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market
presence in South-east Asia & India and partnering in MENA. We aim to serve clients and consumers
through commercial and marketing support using an innovative approach across the Wellesta value
chain. We work with companies to expand their presence in SEA & India as strategic partner for
companies present in these markets and acts as a representative for companies that are not present
in these markets and would like to sell/market their products in the region.
Wellesta Holdings operates in a spectrum of business verticals under our Partner Brands and Own
Brands, including Pharmaceutical, Nutraceuticals, OTC and Medical devices. Being led by industry-
proven leaders at HQ & country level. Wellesta works on extended arm for principals through win-
win partnership and provide superior quality products and services at right price, by working at full
compliance and transparency in business approach.
This joint venture supports the mission of Wellesta to provide cost-effective and high-quality
products and services and help to deliver better patient outcomes in healthcare.
About Rubicon Research Pvt Ltd
Rubicon Research is an IP led, specialty pharmaceutical company that develops, manufactures and
commercializes its value-added formulations for the global market. The company leverages its
proprietary technologies and specialized formulation development skills to provide solutions to
complex delivery challenges, enabling better patient outcomes.
Rubicon Research holds more than 50 issued patents in drug delivery technologies and its portfolio
spans multiple dosage forms, including oral solids, oral liquids, nasal, ophthalmic, injectable, sterile,
topical, drug device combinations, and fixed-dose combinations. Its flagship manufacturing facility
has been inspected by leading global health authorities, including the US FDA and UK MHRA.
Rubicon Research is a portfolio company of General Atlantic, a global growth equity investor with
nearly USD 35 billion in assets under management.
We are pleased to announce the appointment of Mr. Dinesh Nair as Director, Supply Chain for India Business.
Effective from 1st Dec 2019
Mr. Dinesh Nair has been appointed as Director, Supply Chain for Wellesta Healthcare Pvt. Ltd with effect
from 1st December, 2019. Mr. Nair is a seasoned business leader with over 35 years of experience in
Pharmaceutical,
OTC, Medical Nutrition & Food Industry locally & internationally. He was previously Managing Partner at
Integratos
India LLP, India.
His experience in business spans over Asia Pacific and Africa for both MNC’s and Indian Companies. It
encompasses
the setting-up of new businesses, opening-up new Emerging markets, turning around under-performing businesses,
establishing
sales & distribution networks, managing P & L and leading cross-cultural & cross- functional teams
across
geographies.
His career started as Distribution Manger at Themis Pharmaceuticals and Medley Pharma later worked at First
Arabian
department stores, Novartis, Nestle, Equant Consultants Pvt. Ltd and Integratos India LLP.
Mr. Nair completed his post graduate diploma in Marketing & Sales Management and Computer Applications.
He has
obtained a Bachelor degree in Science from Mumbai University, India.
We at Wellesta are very optimistic about opportunities in Indian Healthcare Market & opportunities for
Wellesta
to grow & make strong progress. We are sure that Mr. Nair's experience & leadership will help to achieve
our Vision & Mission in India.
Mr. Nair will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD of
the
Wellesta Group.
We welcome Mr. Dinesh Nair, a Keralite who is now based in Mumbai, to our Wellesta family and wish him
great success
in his future endeavours.
We are pleased to announce the appointment of Mr. Partha Dutt as Director, Marketing & New Product Strategy
for India
business.
Effective from 1st Mar 2020
Mr. Partha Dutt has been appointed as Director, Marketing & New Product Strategy for Wellesta
Healthcare
Pvt. Ltd with effect from March, 2020. Mr. Dutt is a competent professional with over 22 years of experience in
Consumer
Healthcare, OTC and FMCG (Health & Wellness). In his previous role as CEO of Nutrite Healthcare, he was
responsible
for setting up the nutraceutical business from scratch.
He comes with extensive knowledge in various categories and experience in strategic and operational front.
His strength
lies in his ability of working collaboratively with cross-functional teams, taking high levels of ownership and
adding
value to their decision-making.
Mr. Dutt has been in various leadership roles across leading companies like 3M, VLCC, GSK and Novartis. His
experience
spans across various categories like VMS, cough/cold/fever, pain and inflammation, nutritional supplements,
wound
care etc. Mr. Dutt holds a MMS (Marketing)- Business Management and B.Pharm degree from Mumbai University.
We at Wellesta are very optimistic about the opportunities in Indian Healthcare Market & opportunities
for Wellesta
to grow & make strong progress. We are sure that the addition of Mr Partha Dutt to team will help us to
achieve
our Vision & Mission in India.
Mr. Dutt will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD of
the
Wellesta Group.
We welcome Mr. Partha Dutt, who is originally from Kolkata and now based in Mumbai to lead Wellesta
India's
Marketing & New Product Strategy with his expertise and strategic prowess.
We are pleased to announce the appointment of Mr. Paul Lim as Country Head for Singapore and OTC Lead for
Singapore, Malaysia
and Indonesia.
Effective from 1st Mar 2020
Mr. Paul Lim has been appointed as Country Head for Singapore and OTC Lead for Singapore, Malaysia and
Indonesia
with effect from 1st March, 2020.
Mr. Lim previously worked at Church & Dwight where he launched and achieved market leadership in
numerous countries
in the Nasal care and VMS categories as OTC Lead - Asia Pacific. Mr. Lim is a highly motivated and experienced
commercial
leader with over 18 years of experience in the pharmaceutical and consumer health industry across Asia Pacific.
With his expertise and robust experience, he has held various key commercial roles in multinational
companies such
as Pfizer, Alcon and Church & Dwight. He also enabled Alcon Singapore to extend its leadership in the
pharmaceutical
franchise of ophthalmology as Business Unit Head.
He holds Bachelor of Business degree from the University of Central Queensland and has completed his
coursework
for Global MBA from University of London.
We at Wellesta see good opportunity for Singapore Pharma & OTC Market and in other SE emerging markets.
With
addition of Mr. Lim to Wellesta team, would help driving opportunities and meet the Vision and Mission of our
company.
Mr. Lim will report to Milan Paleja, Director of Wellesta Healthcare Singapore Pte Ltd & also Chairman
&
MD of Wellesta Group.
We welcome Mr. Paul Lim, who is now based in Singapore, to our Wellesta family. We look forward for his
dedicated
contribution in the overall management and growth of Wellesta business in Singapore as well as being the Lead
for
the OTC Businesses in Malaysia and Indonesia.
We are pleased to announce the appointment of Ms. Sally Kuah as Country Manager for Malaysia for our Pharma
business w.e.f 1st July, 2021.
Effective from 1st July 2021
Ms. Sally Kuah has been appointed as Country Manager for Wellesta Healthcare Sdn Bhd, Malaysia. This legal
entity will focus on Pharmaceutical Business of Wellesta in Malaysia. Sally will join us from 1st July 2021.
Her last position was the Business Unit Director for MSD Malaysia, Singapore and Brunei. She has extensive
experience with 20 years in pharmaceutical industry in multiple therapeutic areas such as Vaccine, Neurology,
Psychiatry, Diabetes, Ophthalmology and Cardiovascular.
Ms. Sally Kuah started her career as Product Specialist for Sanofi Pasteur and moved to marketing role after 2
years. During her stint in Sanofi Pasteur, she managed both the
paediatric and adults/traveller’s vaccines. After Sanofi, she moved to Novartis as the Product Manager and
continued to take on bigger roles over the years as Sales and Marketing Manager and Franchise Head. In Novartis,
she handled multiple portfolios from neurosciences, ophthalmology, heart failure cardiovascular and diabetes.
She also played an integral role to merge the Alcon and Novartis ophthalmology portfolios and successfully led
the entire team as a combined unit.
Ms. Sally Kuah moved to MSD as the Business Unit Director for the Primary Care Business, with expanded
responsibilities covering 3 countries. She has experience as a member of the Country Leadership Team for more
than 8 years. She has led multiple country-initiated projects which touched on people and transforming work
cultures, process simplifications, pilots and innovations.
She is a science degree graduate in Biotechnology (first class honors) from Universiti Putra Malaysia and holds
an MBA from Charles Sturt University, Australia.
We at Wellesta see good opportunities in Malaysian Pharmaceutical & Nutraceutical Markets. We see a strong
growth opportunity in both segments. We are sure that Ms.
Sally Kuah’s experience and leadership will help our Malaysia business plan for Pharma business to achieve our
vision and mission in Malaysia.Our Nutraceutical, Direct to
Consumer Business in Malaysia will be under Wellesta Truelife Sdn. Bhd. entity which is
led by Mr. Joe Pramesh Ganesaguru.
Both Ms. Sally Kuah & Mr. Joe P will report to Milan Paleja, Chairman and MD of the Wellesta Group.
We welcome Ms. Sally to Wellesta family and wish her all success & joy in her new
position.
We are pleased to announce the appointment of Dr. Hanadi Setiarto as Country Group Head for Wellesta Indonesia w.e.f. 1st October 2024.
Effective from: 1st October 2024
We are pleased to announce the appointment of Dr. Hanadi Setiarto as Country Group Head for Wellesta Indonesia. Before joining Wellesta, Dr. Hanadi was President Director of PT ACTAVIS Indonesia, a TEVA PHARMACEUTICAL subsidiary. He is a seasoned commercial leader with 32 years of experience within the pharmaceutical industry.
Dr. Hanadi began his career in 1992 and held various managerial roles for 12 years at Dumex Alpharma Indonesia (now Actavis) and Bristol Myers Squibb Indonesia. He later joined PT Novartis Indonesia as Commercial Operations Director. He worked for 6 years, where he identified and developed long-run and mid-term strategies for the Primary Care and Vaccine business unit. In early 2010, he established Pfizer’s legal entity, Pfizer Parke Davis, in Indonesia as a part of Pfizer’s global generic initiative while working as Pharma Sales Director/GM Pfizer Generic at PT Pfizer Indonesia.
Dr. Hanadi also worked as Country Manager at Mundipharma Laboratories GmbH, where he defined, developed, and implemented Indonesia’s market entry strategy. Before his previous role as President Director at PT Actavis, Indonesia, Dr. Hanadi was the Overseas Business Director for PT Dexa Medica (Dexa Group) until September 2017. During his tenure, he was responsible for key growth strategies for the export market for DEXA MEDICA in 16 countries within ASIA and AFRICA, and strengthening company operations in each country.
Dr. Hanadi holds a Master’s degree in International Marketing from STIE Labora and a Medical Doctorate in General Medicine from Krida Wacana Christian University, Jakarta. He will report to Mr. Milan Paleja, our Chairman & MD of Wellesta Group.
With Dr Hanadi’s appointment, we have created Wellesta Indonesia in 3 Division’s:
(1) Ethical (2) Medical Devices & Diagnostics (MD & D) (3) Direct to Consumer (DTC)
Mr. Yohannes Sinaga will continue to lead our Ethical Business in Indonesia, and he will be reporting to Dr Hanadi. We are in the process of appointing leaders for MD&D and DTC for Indonesian Business.
We welcome Dr. Hanadi Setiarto to the Wellesta family and wish him great success in his new role.
We are pleased to announce the appointment of Mr. Yohannes Sinaga as Country Manager, PT Wellesta CPI Indonesia.
Effective from 1st May 2020
Mr. Yohannes Sinaga has been appointed as the Country Manager for PT Wellesta CPI Indonesia, effective
from
1st May 2020.
His last position was Chief Marketing Officer for AstraZeneca Indonesia. He has extensive experience with
15 years
in pharmaceutical industry.
Mr. Sinaga has experience in various positions including sales and marketing, as well as various
experiences in
varied therapeutic areas. He has extensive engagement with Medical Association Groups including the association
of
Pediatrician, Psychiatry, Internal Medicine, Hematology – Oncology, Surgical Oncology, Pathology, Pulmonology,
Hepatology,
Nephrology, Virology, Neurology, Rheumatology, Urology, Gynecology, as well as with Government Stakeholders.
Mr. Sinaga’s career started as Product Specialist for Novartis in 2006, then moved to marketing role as a
Product
Manager, he worked with Novartis for 5 years. In 2011, he decided to move to Roche Indonesia as an Oncology
Product
Manager, 1 year later was promoted as a Group Product Manager and later was appointed as Business Unit Head. He
joined
AstraZeneca (AZ) in 2016 as a Business Unit Director for Respiratory Disease as well as to leading Core Products
and later to lead the Learning & Development Department. Mr. Sinaga was a member of AstraZeneca
International
Marketing Excellence Champion with the role to set Respiratory strategy plan to countries in international
region.
Mr. Sinaga holds MBA from IPMI International Business School in Jakarta as well as a Certified
Pharmacist/Apothecary
from University of Padjadjaran Bandung – Indonesia.
We at Wellesta are very optimistic about Indonesian Healthcare Market & opportunities for Wellesta to
progress.
We are sure that with Mr. Sinaga’s leadership the Indonesia team will help achieve our Vision & Mission. Mr.
Sinaga will report to Milan Paleja, Director of PT Wellesta CPI Healthcare & also Chairman & MD of
Wellesta
Group.
We welcome Mr. Yohannes Sinaga to Wellesta family and wish him great success in his new position.
We are pleased to announce a Supply and Licensing collaboration with SGN Nanopharma, Inc. and Cureleads to
launch Nanotherapeutics Optha in SEA and MENA
Effective from 27 Apr 2021
This collaboration aims to establish a
series of nanotherapeutics technology for patients with dry eye diseases. The first product to be launched
will be in the Ophthalmic category.
SGN Nanopharma, Inc. is an innovative, clinical-stage, and revenue-generating developer of
nanotherapeutics. Cureleads is a Dubai/Beirut-based pharmaceutical company, with a market presence in
MENA, that aspires to transform patient’s lives by leading the path to cure. This landmark partnership is a
major stride to fulfill the needs in large, growing therapeutic categories, which helps our patients achieve
better outcomes through high-quality healthcare products.
Talking about this collaboration, Dr. Navdeep Jaikaria, Founder, Chairman, and CEO of SGN Nanopharma,
Inc., said, "We are very excited about this partnership. We plan to bring multiple products to these
growing and emerging markets of Asia and MENA through our partners, Wellesta and Cureleads."
Mohamad Rammal, CEO of Cureleads, said, "We are excited to bring nanotherapeutics technology for
patients with dry eye disease across MENA. This collaboration with SGN Nanopharma will have a huge
impact on patients in the MENA region."
Mr. Milan Paleja, Chairman and Managing Director of Wellesta, shared, "We are excited to bring
enhanced technology products for our patients in Asia and MENA. This will help our dry-eye patients
achieve much better results, compared to currently available products in the market. This collaboration
with SGN Nanopharma and Cureleads is a big step towards getting higher efficiency products for our
patients in Asia and MENA."
We are pleased to announce our Strategic Business Partnership for Middle East & North Africa with Cureleads, a
company headquartered in Dubai & Beirut.
Effective from 9 Sep 2020
We are pleased to announce the collaboration of Wellesta and Cureleads.
Wellesta is a company headquartered in Singapore and support Healthcare companies to expand their reach of
products for larger access to patients & brand building by way of offering sales, marketing & distribution. It
also helps smaller MNC’s & Biotech companies as launch pad for their products to be launched in Asia Pacific.
Wellesta is led by Industry Proven leaders at HQ & Country level.
Cureleads is a company headquartered in Dubai & Beirut and aspires to transform patient’s lives by leading the
path to cure specialty and rare diseases. It is founded by highly profiled industry leaders regionally and
globally.
Cureleads is involved in the business of distribution and marketing of medicinal and pharmaceutical products in
Middle East, Dubai & North Africa.
Wellesta is in the business of marketing, brand creation, sales & distribution of medicinal and Healthcare
products with focus on Asia Pacific.
With this collaboration both companies can help companies to get coverage across Asia Middle East & Africa
(AMEA) geographies. Both companies operate on the principles of High Integrity, Value added partner & Full
transparency for our Principals. This alliance will help companies get a partner which provides excellent reach
in AMEA countries.
Apart from this, both companies will also provide bilateral support for each other through medical talks, health
fairs, newsletters and websites or such other media. They will carry out joint research on the demographics,
risk profiles and care needs of the population in both territories from time to time.
Thus, Wellesta’s goal to support and provide high quality healthcare products & services at optimum price to
improve health access to masses, and Curelead’s goal to lead the transformation of patients’ lives & curing
speciality diseases will be accomplished through this collaboration in Asia Middle East & Africa. Our focus
would be driven through our dedicated efforts, strong in-market experience, best-in class capabilities,
determination and excellent execution.
We are pleased to announce partnership in Indonesia by acquiring majority of shares & management control of
PT Citra
Pharma Indonesia.
Acquired from 1st Dec 2019
We are very pleased to announce our partnership in Indonesia by acquiring majority of shares & management
control of
PT Citra Pharma Indonesia from current shareholders. It will now operate under the new name PT Wellesta CPI
Healthcare
and will be based from Jakarta. PT Citra Pharma Indonesia is in successful operations for last 12-years and have
been partner with MNC players in Pharma and Healthcare sector in the Indonesian market. PT Citra Pharma provides
medical sales & marketing services to MNC in Indonesia with successful and compliant track record.
This company was founded by Pak Budi, Pak Chan, Pak Freddy & Pak Agus. At present PT Wellesta CPI is
led by
Pak Freddy Hidajat as President Director. Indonesia is one of the fastest growing pharmaceutical markets in Asia
and offers us good opportunity to partner with present MNCs in the country & companies who want to enter
Indonesian
market.
Our goal is to provide high quality professional services and support provide high quality healthcare
products at
optimum price to improve health to masses. We foresee this partnership will help accomplish our Vision and
Mission
through PT Wellesta CPI Healthcare in Indonesia. Our focus would be driven through our dedicated efforts, strong
in-market experience, determination and veracity.
Board of Both Companies post Signature
Sales Team Meeting - PT Wellesta CPI
Sales Team Meeting with PT Wellesta CPI T-Shirts
Abdul Latif Jameel Health and Wellesta announce collaboration to bring the innovative Butterfly iQ+TM Point-Of-Care
Ultrasound (POCUS) solution to serve the medical imaging needs of over 1.3 billion people across India
Effective from 1st October 2022.
The Butterfly iQ+ is the only ultrasound transducer that can perform whole-body imaging in a single handheld
probe using
semiconductor technology to provide point-of-care ultrasound-driven insights.
Founded in 2020, Abdul Latif Jameel Health was created as a response to the ongoing global disparity in
access
to modern
medical care, focusing on accelerating healthcare inclusion across the Global South.
Dubai UAE & Mumbai, India: October 19, 2022: Abdul Latif Jameel Health, part of international diversified family
business Abdul Latif Jameel, and
Wellesta Holdings Pte. Ltd., a Singapore headquartered company providing
marketing and commercialization support to the healthcare sector
in South East Asia, India & partnering in MENA, today announced an important new agreement for the marketing and
distribution of the Butterfly iQ+TM point-of-care ultrasound device in The
Republic of India.
The innovative Butterfly iQ+TM1 is the world's first single probe,
whole-body
handheld point-of-care ultrasound solution.
As part of its new agreement with Abdul Latif Jameel Health, Wellesta will register Butterfly iQ+TM in India and start
promoting and selling the product in the country in the fourth quarter of 2022, bringing this technology to a
potential
1.2 million registered physicians in the country2.
Today, more than 4.7 billion around the world lack access to medical imaging3 ,
from underserved communities in the
United States to remote areas of Africa. The Butterfly iQ+TM aims to remedy
this
situation. Fusing semiconductors,
artificial intelligence, and cloud technology, Butterfly has made it possible to usher in a new era of medical
imaging
and with it, healthcare.
This new collaboration will offer greater distribution of Butterfly iQ+TM to
physicians in India thereby expanding the
capabilities of the practitioners in making informed decisions thereby accelerating access to modern medical
care
for
those who need it most.
Butterfly iQ+TM, is revolutionizing medical imaging. It is a hand-held 4 in
1
single probe whole-body innovative
point-of-care ultrasound device powered by the world’s only Ultrasound–on-Chip™ technology.
This point of care device with over 20 default pre-sets is compatible with both iOS and Android smart devices
and
comes
complete with battery back, wireless charging, cloud storage, customized app., software and AI support.
Hailed as potentially the ‘stethoscope of the future’, the Butterfly iQ+TM
transforms what can sometimes be complex
processes, into one connected and integrated point-of-care ultrasound (POCUS) system to help collect advanced
imaging,
perform rapid assessments, and guide critical procedures. It allows the sharing of results seamlessly with
doctors
across the globe to help read and interpret scans.
Speaking about this new collaboration, Mr.
Milan Paleja, Chairman and Managing Director, Wellesta, said: “I am very
excited to partner with Abdul Latif Jameel Health to market Butterfly iQ+TM in
India to bring this breakthrough
Ultrasound-on-ChipTM technology in the Butterfly probe to this market. Its
versatile, innovative ultrasound solution will
assist healthcare professionals to obtain point-of-care Ultrasound-driven insights - – across the vast country
with a geographically disperse population to improve access to primary healthcare.”
Mr. Paleja added his thanks to deal advisor, Healthark Insights who
supported this collaboration with Abdul Latif Jameel
Health.
Akram Bouchenaki, Chief Executive Officer,
Abdul
Latif Jameel Health added: “Abdul Latif Jameel is addressing tangible
real-world needs today, for a better tomorrow. We are focused on health care inclusion, accelerating access to
modern
medical care for those who need it most.
“We believe in realizing the true power of deep local knowledge, relationships, and partnerships to get the
very
best
results for the communities we serve. In India, I am proud to collaborate with Wellesta who share our vision
of
improving live and lives across the Global South.”
[1] Butterfly iQ+TM is a Class IIa / Class B / Class II / Class II / IIa
ultrasound system designed for diagnostic imaging
by trained healthcare professionals. Carefully read and understand all cautions, warnings and operational
instructions
prior to use.
[2] In 2020, there were over 1.2 million doctors registered with the Indian Medical Council.
About Wellesta Wellesta Holdings Pte Ltd is a healthcare company headquartered in
Singapore
with a direct market presence in Southeast
Asia & India and partnering in MENA. We aim to serve clients and consumers through commercial and marketing
support
using an innovative approach across the Wellesta value chain. We work with companies to expand their presence
in
Southeast Asia & India as a strategic partner for companies present in these markets and act as a
representative
for
companies that are not present in these markets and would like to sell/market their products in the region.
Wellesta Holdings operate in a spectrum of business verticals under our partner brands and own brands
including
pharmaceutical, nutraceuticals, OTC and medical devices, led by industry-proven leaders at HQ & Country level.
Wellesta
works as an extended arm for our principals through win-win partnership and provides superior quality products
and
services at the right price, by working at full compliance and transparency in our business approach. This
joint
collaboration supports the mission of Wellesta to provide cost-effective and high-quality products and
services
and help
to deliver better patient outcomes in healthcare.
For further information, visit: www.wellesta.com and our LinkedIn
page.
About Abdul Latif Jameel Health
Backed by Abdul Latif Jameel, one of the most respected diversified family
businesses and investors with a 75-year
heritage, deep roots, and established networks alongside a multi-sector presence in 30 countries across six
continents,
Abdul Latif Jameel Health is uniquely positioned as a trusted partner in realizing major innovations and
opportunities
in the healthcare world.
Abdul Latif Jameel Health reflects the Jameel family’s long-established
commitment to innovating for a better future
through Community Jameel, an international organization supporting science and technology-led solutions to
global
challenges. Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health
(Jameel
Clinic) in September 2018 – which has rapidly become the very epicenter of AI and healthcare at MIT – and the
Abdul
Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) co-founded with Imperial College
London,
in October 2019, using novel data analytics to reduce global risk of preventable disease most recently
including
the
2020 COVID-19 pandemic, and strengthening health systems in the most fragile settings.
Abdul Latif Jameel Health takes this commitment into the commercial environment addressing tangible real-world
needs
today, for a better tomorrow. It is focused on health care inclusion in the global south, accelerating access
to
modern
medical care for those who need it most by opening up/growing new markets for distribution of existing
solutions
and
investing in the future of MedTech.
The Jameel Investment Management Company (JIMCO) the global investment arm of the Jameel Family, actively
invests
in
innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of
core
industries driving the global economy through its’ investments that span medical and healthcare industries,
from
pharmaceuticals and vaccines to cutting-edge medical technology, along with emergent technologies across
FinTech,
InsurTech, electric vehicles and future mobility solutions.
For further information, visit: https://aljhealth.com and our brand video
here.
Media Contact: Email aljhealth@edelman.com or telephone: +971 54
996
9935 (GMT +4 hours UAE)
For general inquiries: info@aljhealth.com
For adverse event reporting or medical enquiries: safety@aljhealth.com / T:+971 4 448 0905
The term “Abdul Latif Jameel” refers broadly to several distinct, separate and independent legal entities.
Abdul
Latif
Jameel is not itself a corporate entity, association or conglomerate run by an overarching parent company but
merely
refers to a group of distinct and wholly separate legal entities that are collectively referred to as Abdul
Latif
Jameel. Abdul Latif Jameel is not a corporate group as defined in section 1161(5) of the Companies Act 2006.
This document may contain forward-looking statements. Forward-looking statements are statements regarding
matters
other
than historical fact, such as future results, events, activities, developments or circumstances or the
beliefs,
plans or
expectations of Abdul Latif Jameel Health or Abdul Latif Jameel entities or their respective management.
Forward-looking statements often can be identified by the use of words such as ‘expect’, ‘project’,
‘anticipate’,
‘plan’, ‘estimate’, ‘believe’, ‘predict’, ‘intend’, ‘potential’, ‘possible’, ‘probable’, ‘likely’, ‘forecast’,
‘guidance’, ‘outlook’, ‘goal’, ‘target’, ‘may’, ‘will’, ‘should’ or ‘could’ or other similar terms or phrases.
However,
the absence of such words does not mean that a particular statement is not forward looking.
Forward-looking statements are based on expectations and assumptions at the time of such statements and are
subject to
numerous risks and uncertainties, many of which are outside the control of Abdul Latif Jameel Health or Abdul
Latif
Jameel entities. Should any of such expectations or Further, any forward-looking statement speaks only as of
the
date on which it is made, and neither Abdul Latif Jameel
Health nor Abdul Latif Jameel assumes, and hereby disclaims, any obligation to correct or update any
forward-looking
statement, whether as a result of new information, future events or otherwise. All forward-looking statements
made
by
Abdul Latif Jameel Health, Abdul Latif Jameel, or by any person on behalf of any of them, whether communicated
in
writing, electronically or orally, are qualified in their entirety by the foregoing cautionary statements.
No Offer or Solicitation
This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect
to
any
securities or in respect of the potential transaction and shall not constitute an offer to sell or the
solicitation of
an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such
offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any
such
jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements
of
Section 10 of the Securities Act, or an exemption therefrom.
Important Note:
The Butterfly iQ+ product is not yet registered/marketed in all markets.
No News Found
Country Presence
Singapore
India
Malaysia
Indonesia
Wellesta Healthcare Pvt. Ltd
Unit 3A, Level 2, The Centrium, Phoenix Market City, LBS Marg, Kurla, Mumbai - 400070
Singapore
India
Malaysia
Indonesia
